Score Five For FDA: Shire's Vyvanse Entitled To NME Exclusivity, Court Finds

FDA scored a victory when a district court ruled that it was correct in awarding five years of market exclusivity to Shire's attention-deficit hyperactivity disorder drug Vyvanse (lisdexamfetamine)